Myricx Bio
Developing the first class of ADCs based on NMT inhibition
London, United Kingdom · Founded 2019 · $113.0M raised
- Headquarters
- London
- Employees
- 1–10
- Founded
- 2019
- Business Model
- B2B
- Website
- myricx.bio
- Total Funding
- $113.0M
- Last Round
- $113.0M Venture RoundJul 2024
- Rounds
- 1
About
Myricx Bio is a UK biotech company focused on discovering and developing a novel class of payloads for antibody drug conjugates (ADCs) based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer. Founded on world-leading NMT biology and chemistry research, Myricx is advancing a pipeline of NMTi-ADC programs against validated oncology targets including B7-H3 and HER2 toward clinical development.
Summary
Myricx Bio is a Biotech company based in London, United Kingdom, founded in 2019. It has raised $113.0M in total across 1 round, most recently a $113.0M Venture Round round in Jul 2024.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jul 2024
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...